Thus, in MSC therapy, since the administrated MSCs produce a large amount of EVs by incorporating adiponectin into the cells via T-cadherin expressed on the membrane surface, the action of EVs on the heart improves the cardiac function of the heart failure model. Here, ADIPOQ is linked to heart failure.